FDA signals openness to innovative trial designs for psychedelic therapies

FDA regulators said they are willing to consider more flexible approaches for evaluating psychedelic medicines.

The agency noted that studies could use active comparators instead of placebo, which may better reflect real world treatment conditions.

This comment follows recently finalized FDA guidance that encourages innovative trial designs for emerging therapies.

Developers of psychedelic treatments may now have clearer options for designing pivotal trials, potentially speeding development timelines.